EUVIMEDEUVIMED entdecken
Editorial

Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease

Pradeep Natarajan iD

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2405647 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Pradeep Natarajan. Beteiligte Einrichtung: From the Department of Medicine and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School - both in Boston. Hauptthemen laut MEDLINE: Coronary Artery Disease, PCSK9 Inhibitors, RNA, Small Interfering, RNAi Therapeutics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasingly widespread availability of genomic sequencing has enabled the identification of persons and families with uniquely favorable traits, including a very low incidence of clinical events. Such exceptional persons across diverse communities are playing an important role in the genesis of medicines for common cardiovascular diseases. The discovery of proprotein convertase subtilisin–kexin type 9 (PCSK9) as a therapeutic target for coronary artery disease established a playbook. Approximately 20 years ago, positional cloning of a novel candidate locus of families with familial hypercholesterolemia living in France and Utah identified gain-of-function variants in PCSK9 . In short course, targeted sequencing of PCSK9 . . .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseasePCSK9 InhibitorsRNA, Small InterferingRNAi TherapeuticsHumansProprotein Convertase 9Angiopoietin-Like Protein 3Apolipoprotein C-IIIGain of Function MutationGenetic Predisposition to Disease

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9APOC3 protein, humanANGPTL3 protein, humanAngiopoietin-Like Protein 3Apolipoprotein C-IIIRNA, Small Interfering

Autor:innen und Institutionen

  • From the Department of Medicine and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School - both in Boston.

ORCID-Profile: Pradeep Natarajan

Zitieren

APA

Natarajan, P. (2024). Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease. New England Journal of Medicine. https://doi.org/10.1056/nejme2405647

Vancouver

Natarajan P. Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease. New England Journal of Medicine. 2024. doi:10.1056/nejme2405647

BibTeX
@article{Natarajan2024,
  author = {Natarajan, Pradeep},
  title = {Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2405647}
}
Kostenlos starten →